FDA Approves Brentuximab Vedotin with Lenalidomide and Rituximab for Relapsed or Refractory Large B-Cell Lymphoma By Ogkologos - March 27, 2025 486 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ECHELON-3 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR EMA Publishes Guidance to Provide Key Methods and Good Regulatory Practices... November 8, 2021 EMA Recommends Extension of Indications for Sugemalimab October 28, 2025 “Giving something back”: our supporters are the beating heart of what... August 17, 2022 EMA Recommends Granting a Marketing Authorisation for Azacitidine May 3, 2021 Load more HOT NEWS Early-onset cancer: why are more young adults being diagnosed? How Early Cancer Detection and Diagnosis Saved My Life Twice: A... One Year in Cancer Research and Much to Celebrate Oncofertility: Creating a Bridge Between Cancer Care and Reproductive Health
